AMPK activation counteracts cardiac hypertrophy by reducing O-GlcNAcylation

Citations Over TimeTop 10% of 2018 papers

Abstract

AMP-activated protein kinase (AMPK) has been shown to inhibit cardiac hypertrophy. Here, we show that submaximal AMPK activation blocks cardiomyocyte hypertrophy without affecting downstream targets previously suggested to be involved, such as p70 ribosomal S6 protein kinase, calcineurin/nuclear factor of activated T cells (NFAT) and extracellular signal-regulated kinases. Instead, cardiomyocyte hypertrophy is accompanied by increased protein O-GlcNAcylation, which is reversed by AMPK activation. Decreasing O-GlcNAcylation by inhibitors of the glutamine:fructose-6-phosphate aminotransferase (GFAT), blocks cardiomyocyte hypertrophy, mimicking AMPK activation. Conversely, O-GlcNAcylation-inducing agents counteract the anti-hypertrophic effect of AMPK. In vivo, AMPK activation prevents myocardial hypertrophy and the concomitant rise of O-GlcNAcylation in wild-type but not in AMPKα2-deficient mice. Treatment of wild-type mice with O-GlcNAcylation-inducing agents reverses AMPK action. Finally, we demonstrate that AMPK inhibits O-GlcNAcylation by mainly controlling GFAT phosphorylation, thereby reducing O-GlcNAcylation of proteins such as troponin T. We conclude that AMPK activation prevents cardiac hypertrophy predominantly by inhibiting O-GlcNAcylation.

Related Papers

• → Thienopyridone Drugs Are Selective Activators of AMP-Activated Protein Kinase β1-Containing Complexes(2008)250 cited
• → [Research progress of Adenosine 5'-monophosphate-activated protein kinase in the regulation of glycolipid metabolism].(2019)4 cited
• → Homogenous Fluorescent Assays for Characterizing Small-Molecule Activators of AMP-Activated Protein Kinase (AMPK)(2008)2 cited
• New findings in AMP-activated protein kinase(2014)
• 돌외 추출물로부터 순수 분리된 saponin 계열의 화합물인 Damulin B에 의한 AMP-activated protein kinase (AMPK)의 활성화 기작에 대한 연구(2011)